November 2024. Examines commercial plans' management of high and ultra high-cost therapies, discusses financing and contracting mechanisms, and evaluates best-in-class manufacturer support and commercial MCO needs going forward.
2024 Research
October 2024. Reviews issues in specialty pharmacy dispensing and distribution of rare disease and gene therapy medications. Examines network considerations, specialty pharmacy capabilities, contracting approaches, and best-in-class manufacturer engagement/support.
August 2024. Reviews contract prevalence with key commercial payer segments, most common contracting approaches, and rebate/discount amounts offered across 40+ therapeutic areas spanning traditional, specialty and oncology.
-
A number of innovative rare disease and gene therapy treatments have entered the market, requiring novel utilization management, financing, and contracting approaches. HIRC’s report, Rare Disease...
-
Specialty pharmacies are developing robust and unique capabilities to support the growing market of rare disease & gene therapies, and can serve as strong partners in patient access and adherence...
-
Pharmaceutical manufacturer contracting is a key element of account engagement to enhance and/or maintain market access; however, the contracting landscape can vary greatly by therapeutic area. HIRC'...
HIRC Special Report Series
Special Report Topics
Special report topics vary annually based upon the current health care environment. Research directors and consultants select topics or insights that are highly relevant, of high interest, and/or are critical for manufacturers to be aware of. Special reports often draw upon data across HIRC services, allowing readers to glean insights into high level topics across varying market segments, channels, and/or therapeutic areas.
